| |
De-risk your biological product supply with a seamless technology transfer. With more than 50 new product introductions in the last 12 months across biological modalities, Lonza is an experienced partner for clinical and commercial biological product manufacturing in liquid/lyo vials and prefilled syringes. Discover how.
|
|
Today’s Big NewsMay 17, 2024 |
| By Kevin Dunleavy Seven months after Amgen’s chief medical officer referred to trial results for the company's investigational lung cancer immunotherapy as a “watershed moment,” the FDA has signed off on Imdelltra (tarlatamab) to treat patients with extensive-stage small-cell lung cancer (ES-SCLC). |
|
|
|
By James Waldron Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while clearing space in its own pipeline and laying off 18% of its employees in the process. |
By Conor Hale On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible competitor. |
By Andrea Park AbbVie’s newest psoriasis awareness-raising campaign is taking the skin condition out of the spotlight. |
|
Wednesday, May 22, 2024 | 10am ET / 7am PT In this webinar, we'll explore how emerging technologies aid Medical Affairs teams in understanding their research's online influence and reaching the right audiences. Topics include analyzing audience engagement, identifying influential opinion leaders, monitoring real-world conversations, and discovering emerging researchers. Register now.
|
|
By Angus Liu China-made PD-1 inhibitors continue to struggle at the FDA. This week, the U.S. agency rejected Elevar Therapeutics and Jiangsu Hengrui Pharma's PD-1 combination in liver cancer. |
By Nick Paul Taylor Bayer’s master plan for its OASIS program is coming together, with the German drugmaker posting phase 3 data that suggest it could challenge Astellas for a recently unlocked menopause market. |
By Conor Hale After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a breakthrough designation from the FDA. |
By Andrea Park As it prepares to push its kidney care portfolio out of the nest, Baxter International isn’t branching out too widely with the new company’s branding materials. |
By Fraiser Kansteiner A committee of the European Medicines Agency on Friday called for the withdrawal of preterm birth drugs containing 17-hydroxyprogesterone caproate (17-OHPC), citing safety and efficacy concerns. |
By Max Bayer,Gabrielle Masson Atai Life Sciences, one of the leading shareholders in psilocybin drug developer Compass Pathways, is swapping CEOs. |
By Andrea Park The company formerly known as First Wave BioPharma has found itself on dry land with a decidedly non-aquatic new moniker. |
By Helen Floersh The rare, deadly blood clots triggered by an autoimmune response to the COVID-19 vaccines from Johnson & Johnson and AstraZeneca seem to be caused by a gene that’s also responsible for an unusual but almost identical reaction to the virus that causes the common cold. The findings could have implications for future vaccines. |
Fierce podcasts Don’t miss an episode |
| This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
---|
|
|
|
Wednesday, June 5, 2024 | 2pm ET / 11am PT Delayed diagnosis of autoimmune diseases is common due to subjective symptoms, lack of definitive testing, and gender bias. This can cause worsening symptoms and disease progression, while simultaneously leading to missed research opportunities and reduced revenue for pharma. Join us to learn about key advancements in RWD for helping address these issues. Register now.
|
|
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|